Phase 3 Allogeneic Clinical Trials
7 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–7 of 7 trials
Recruiting
Phase 2Phase 3
VABu Conditioning in Elderly AML HSCT
Acute Myeloid Leukemia (AML)Allogeneic Hematopoietic Stem Cell Transplantation Recipient
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07583888
Recruiting
Phase 3
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Phase 3
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
Allogeneic Hematopoietic Cell TransplantGraft-Versus-Host Disease
Shanghai Jiao Tong University School of Medicine316 enrolled1 locationNCT06705062
Recruiting
Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 3
Use of Tocilizumab (TCZ) to prevent acute graft versus host disease (GVHD) randomized trial
Acute graft versus host disease (GVHD) post HLA-matched allogeneic haematopoietic progenitor cell transplantation (HPCT)
Royal Brisbane and Women's Hospital110 enrolled1 locationACTRN12614000266662
Withdrawn
Phase 3
A Phase III Study Comparing Low Dose Cyclosporine, Methotrexate And Prednisone Versus Standard Dose Cyclosporine and Methotrexate As Graft Versus Host Disease Prophylaxis In Myeloblative Allogeneic Stem Cell Transplantation (ALLG BM10 trial). (Incorporating an Open-Label Sub-study Investigating The Use Of Valganciclovir In The Prevention Of Cytomegalovirus Infection In Hematopoietic Stem Cell Transplant Recipients (ML20712))
Prevention Of CytomegalovirusCell Transplant RecipientsProphylaxis In Myeloblative+3 more
Australasian Leukaemia and Lymphoma Group300 enrolled1 locationACTRN12607000347460